Cited by 32Pulmonary Hypertension Research and TreatmentsNitric Oxide and Endothelin EffectsAngiogenesis and VEGF in Cancer

Therapeutics Targeting of Dysregulated Redox Equilibrium and Endothelial Dysfunction

Risbano, Michael G., Gladwin, Mark T.·2013·Handbook of Experimental Pharmacology

Integrity signals

Registry

Crossref · 10.1007/978-3-642-38664-0_13

Cites

234 of 234 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NOX2 docking sequence-tat (NOX2ds-tat) is the first isoform-specific NOX inhibitor, a peptide based on the sequence of the B-loop of NOX2.

    “NOX2 docking sequence-tat (NOX2ds-tat), the first isoform-specific NOX inhibitor, is a peptide based on the sequence of the B-loop of NOX2 (199, 218, 782).”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Risbano, M. G., & Gladwin, M. T.
Affiliations
University of Pittsburgh (US)
Corresponding author
Gladwin, Mark T.
Venue
Handbook of Experimental Pharmacology
Published
2013
Volume
218
Pages
315-349
ISSN
  • 0171-2004 (ISSN-L)
  • 1865-0325
OpenAlex
W151270876
Cited by
32
References
234
Citations by year
2026: 1 · 2023: 2 · 2021: 6 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 2 · 2014: 4
FWCI
21.81
Type
book chapter
Language
en
Open access
closed
Locations
  • Handbook of experimental pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Heart, Lung, and Blood Institute (R01HL098032)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Physiology › Nitric Oxide and Endothelin Effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Keywords
pulmonary arterial hypertension, endothelial dysfunction, redox homeostasis, reactive oxygen species, reactive nitrogen species, endothelial nitric oxide synthase, eNOS uncoupling, soluble guanylate cyclase, phosphodiesterase-5 inhibition, nitric oxide donors, endothelin-1, prostacyclin, NADPH oxidase, xanthine oxidase, mitochondrial complex III, peroxynitrate, free hemoglobin, asymmetric dimethylarginine, pulmonary vascular remodeling, vasodilator therapy
MeSH terms
Animals, Endothelium, Vascular, Humans, Hypertension, Pulmonary, Nitric Oxide, Oxidation-Reduction, Reactive Oxygen Species, Oxidative Stress, NADPH Oxidases, Nitric Oxide Donors, Nitric Oxide Synthase Type III, Phosphodiesterase 5 Inhibitors, Familial Primary Pulmonary Hypertension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review